New intraprostatic injectables and prostatic urethral lift for male LUTS

Abstract

Treatment modalities for male lower urinary tract symptoms (LUTS) comprise a broad spectrum of medical and surgical options. Interest is growing in minimally invasive treatment options, which should ideally be performed in an outpatient setting and have a short recovery time, durable efficacy and a good safety profile. The preservation of all aspects of sexual function, including antegrade ejaculation, seems to be increasingly important for patients. Initial experimental data on new minimally invasive procedures—such as the intraprostatic injection of novel agents including botulinum neurotoxin A (BoNT-A), NX-1207 and PRX302—were promising, but clinical trials have not confirmed the findings. Trials of the mechanical prostatic urethral lift device—Urolift^® (Neotract, Inc., USA)—have been positive, but further long-term results are needed to confirm its beneficial effects.